COMPANY
Rock Bio: Harnessing the power of Glyco-Engineering for disease prevention and treatmentRock Bio is a Glyco-Engineering company dedicated to the development of better vaccines and antibody drugs through manipulation of sugar on the glycoproteins of interest. As one of the most complex and least understood biological processes, glycosylation plays a crucial role in normal physiology and a wide range of disease states, including infectious diseases, cancer, and autoimmune disorders. Over the past few decades, the field of glyco-engineering has been steadily refining its techniques, bridging the gap between scientific exploration and practical application. The progress is positioning the field for major impacts on disease prevention and treatment. At the forefront of this trend, Rock Bio is well poised to take advantage of these developments.
Utilizing our advanced glycoengineering technology and AI-assisted glycosylation design and optimization platform, we precisely modulate glycan structures on key molecules to develop innovative vaccines and antibody therapies. Our low-sugar universal vaccines offer broadly protective immunity, while glyco-optimized biobetters enhance the safety and efficacy of therapeutic antibodies.
Founded in 2021 and built upon a series of glycoengineering technologies through exclusive licensing from Academia Sinica, Rock Bio now has a team of 16 full time employees and four consultants with two sites of operation. Our Taipei site is the headquarter and houses our preclinical R&D. Our clinical development team operates from our Boston site.
Investigational New Drug (IND) application of RBM001, our first low-sugar universal vaccine program, receives approval from the U.S. FDA.
Low-sugar Universal influenza mRNA Vaccine receives the “Moderna Taiwan mRNA Innovation Awards”
Taipei office launched at BioHub Taiwan
Exclusive licensing agreements on key glycoengineering technologies with Academia Sinica,
Acquisition of US subsidiary, Rock BioTherapeutics, Inc.
Incorporated
